Old North State Wealth Management LLC Buys 4,685 Shares of GSK plc (NYSE:GSK)

Old North State Wealth Management LLC grew its stake in shares of GSK plc (NYSE:GSK) by 87.1% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 10,065 shares of the pharmaceutical company’s stock after purchasing an additional 4,685 shares during the period. Old North State Wealth Management LLC’s holdings in GSK were worth $341,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in GSK. Verity Asset Management Inc. grew its stake in shares of GSK by 20.7% in the 4th quarter. Verity Asset Management Inc. now owns 16,420 shares of the pharmaceutical company’s stock worth $545,000 after buying an additional 2,813 shares during the last quarter. CENTRAL TRUST Co grew its stake in shares of GSK by 5.6% in the fourth quarter. CENTRAL TRUST Co now owns 7,756 shares of the pharmaceutical company’s stock worth $262,000 after acquiring an additional 414 shares during the last quarter. Spire Wealth Management bought a new position in shares of GSK during the fourth quarter valued at $77,000. Caprock Group LLC grew its position in GSK by 7.7% during the 4th quarter. Caprock Group LLC now owns 19,942 shares of the pharmaceutical company’s stock valued at $684,000 after purchasing an additional 1,424 shares during the last quarter. Finally, New Wave Wealth Advisors LLC increased its stake in GSK by 13.2% during the 4th quarter. New Wave Wealth Advisors LLC now owns 10,524 shares of the pharmaceutical company’s stock valued at $356,000 after purchasing an additional 1,226 shares in the last quarter. Hedge funds and other institutional investors own 15.74% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on GSK shares. StockNews.com downgraded GSK from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, January 21st. Deutsche Bank Aktiengesellschaft cut shares of GSK from a “buy” rating to a “hold” rating in a report on Friday, November 15th. Guggenheim lowered GSK from a “buy” rating to a “neutral” rating in a research note on Thursday, October 31st. Finally, Jefferies Financial Group lowered GSK from a “buy” rating to a “hold” rating and cut their price target for the company from $53.00 to $39.50 in a report on Tuesday, November 12th. Six equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and three have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $43.25.

GSK Price Performance

Shares of GSK stock opened at $34.84 on Wednesday. The company has a market capitalization of $72.22 billion, a P/E ratio of 22.63, a P/E/G ratio of 1.38 and a beta of 0.64. The company’s 50-day simple moving average is $34.08 and its two-hundred day simple moving average is $37.64. GSK plc has a one year low of $31.72 and a one year high of $45.92. The company has a debt-to-equity ratio of 0.98, a current ratio of 0.81 and a quick ratio of 0.53.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.